Hallmarks of cancer: interactions with the tumor stroma.

By K. Pietras, A. Ostman. Experimental Cell Research, 2010

1,187 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/63a69f6a2fa9f7a07a59cbed9e175adc1995bca7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

Citations in the corpus

Identification of tumor epithelium and stroma in tissue microarrays using texture analysis (2012, methodology): “It has been proposed that induction or loss of certain proteins in the stroma may be critical in promoting the metastatic phenotype in cancers [10].”
Hallmarks of cancer: the next generation. (2011, positive): “Genetic and pharmacological perturbation of the recruitment and association of pericytes has demonstrated the functional importance of these cells in supporting the tumor endothelium (Pietras and Ostman, 2010; Gaengel et al., 2009; Bergers and Song, 2005).”
Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. (2011, background): “Most of our knowledge on stroma-promoting metastatic events comes from studies on cancer-associated fibroblasts or infiltrating immune cells (Joyce and Pollard, 2009; Pietras and Ostman, 2010).”
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities (2014, background): “Loss of metallothioneins that chelate and store intracellular zinc promotes a wild-type conformation of misfolded p53 (Puca et al., 2009) and addition of zinc to the conformational mutants G245C and G245D p53 partially restored the wild-type conformation (Pintus et al., 2013).”
Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854) (2013, background): “The stromal compartment of tumors, consisting of fibroblasts, endothelium, adipocytes, and extracellular matrix (ECM), is essential for tumor growth and progression [2].”
Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. (2020, background): “org clusters (1, 2, 5) belong to the inflammatory (“iCAF”) subgroup and five CAF-S1 clusters (0, 3, 4, 6, 7) to the myofibroblastic (“myCAF”) subgroup, iCAF and myCAF having been previously identified in pancreatic cancer (7, 16, 26).”
Fibroblast heterogeneity in the cancer wound (2014, background): “However, there is no consensus on their molecular definition (Kalluri and Zeisberg, 2006; Orimo and Weinberg, 2007; Pietras and Ostman, 2010; Xing et al., 2010).”
Carcinoma-associated fibroblasts: orchestrating the composition of malignancy (2016, background): “, a dramatic deposition of ECM proteins (Kalluri and Zeisberg 2006; Pietras and Ostman 2010).”
Accessories to the crime: functions of cells recruited to the tumor microenvironment. (2012, positive): “A number of studies have implicated CAFs in the capability to limit the impact on tumor growth and progression of cancer cell apoptosis (Kalluri and Zeisberg, 2006; Loeffler et al., 2006; Pietras and Ostman, 2010).”
Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy (2014, positive): “Cancer-associated fibroblast-like cells (CAFs) in the tumor stromahavebeenshown toexert aprofound influenceon the initiation and progression of human cancer (Bhowmick et al., 2004; Kalluri and Zeisberg, 2006; Pietras and Ostman, 2010; Räsänen andVaheri, 2010;Shimodaet al., 2010).”
Basic and therapeutic aspects of angiogenesis. (2011, neutral): “Role of Cancer-Associated Fibroblasts in Tumor Vessel Vascularization Another stromal cell type gaining increasing attention is the cancer-associated fibroblast (Crawford and Ferrara, 2009a; Nyberg et al., 2008; Pietras and Ostman, 2010).”
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis (2014, background): “Shown are tumour-derived factors that act to affect: (1) the initiating tumour from which they were derived; (2) distant tissues before metastatic dissemination; or (3) colonization and progression of disseminated micrometastases at distant anatomical sites.”